Explaining the increased health care expenditures associated with gastroesophageal reflux disease among elderly Medicare beneficiaries with chronic obstructive pulmonary disease: A cost-decomposition analysis

International Journal of COPD

Volumn 9, Issue , 2014, Pages 339-348

  Ajmera, Mayank ^a   Raval, Amit D ^a   Shen, Chan ^b   Sambamoorthi, Usha ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Blinder Oaxaca linear decomposition; Comorbidities; Esophageal disease; Geriatrics; Respiratory disease

Indexed keywords

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; FEMALE; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HEALTH CARE PRACTICE; HUMAN; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRESCRIPTION; RETROSPECTIVE STUDY;

BLINDER-OAXACA LINEAR DECOMPOSITION; COMORBIDITIES; ESOPHAGEAL DISEASE; GERIATRICS; RESPIRATORY DISEASE;

AGE FACTORS; AGED; COMORBIDITY; COSTS AND COST ANALYSIS; CROSS-SECTIONAL STUDIES; FEE-FOR-SERVICE PLANS; FEMALE; GASTROESOPHAGEAL REFLUX; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; LEAST-SQUARES ANALYSIS; LINEAR MODELS; MALE; MEDICARE; MODELS, ECONOMIC; MULTIVARIATE ANALYSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 84906564307     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S59139     Document Type: Article

References (43)

1. Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). Global Strategy for Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2011. Barcelona: Global Initiative for Chronic Obstructive Pulmonary Disease; 2011. Available from: http://www. goldcopd. org/uploads/users/files/GOLD_Report_2011_Feb21. pdf. Accessed February 26, 2014.
2. nhlbi. nih. gov [homepage on the Internet]. 2012 NHLBI mortality and morbidity chartbook. National Heart, Lung, and Blood Institute; 2012 [updated May 2013]. Available from: http://www. nhlbi. nih. gov/resources/docs/cht-book. htm. Accessed February 26, 2014.
3. Han MK. Update in chronic obstructive pulmonary disease in 2010. Am J Respir Crit Care Med. 2011; 183(10): 1311-1315.
4. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013; 5: 235-245.
5. Dalal AA, Shah M, D'Souza AO, Rane P. Costs of COPD exacerbations in the emergency department and inpatient setting. Respir Med. 2011; 105(3): 454-460.
6. Oostenbrink JB, Rutten-van Mölken MP. Resource use and risk factors in high-cost exacerbations of COPD. Respir Med. 2004; 98(9): 883-891.
7. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest. 2000; 117(2): 5S-9S.
8. Stuart B, Doshi JA, Briesacher B, Wrobel MV, Baysac F. Impact of prescription coverage on hospital and physician costs: a case study of Medicare beneficiaries with chronic obstructive pulmonary disease. Clin Ther. 2004; 26(10): 1688-1699.
9. Donaldson GC, Müllerova H, Locantore N, et al. Factors associated with change in exacerbation frequency in COPD. Respir Res. 2013; 14: 79.
10. Patel AR, Hurst JR. Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Rev Respir Med. 2011; 5(5): 647-662.
11. Burge PS. Prevention of exacerbations: how are we doing and can we do better? Proc Am Thorac Soc. 2006; 3(3): 257-261.
12. Ozyilmaz E, Kokturk N, Teksut G, Tatlicioglu T. Unsuspected risk factors of frequent exacerbations requiring hospital admission in chronic obstructive pulmonary disease. Int J Clin Pract. 2013; 67(7): 691-697.
13. Rascon-Aguilar IE, Pamer M, Wludyka P, et al. Role of gastroesophageal reflux symptoms in exacerbations of COPD. Chest. 2006; 130(4): 1096-1101.
14. Terada K, Muro S, Sato S, et al. Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax. 2008; 63(11): 951-955.
15. Sakae TM, Pizzichini MM, Teixeira PJ, da Silva RM, Trevisol DJ, Pizzichini E. Exacerbations of COPD and symptoms of gastroesophageal reflux: a systematic review and meta-analysis. J Bras Pneumol. 2013; 39(3): 259-271.
16. Kim J, Lee JH, Kim Y, et al. Association between chronic obstructive pulmonary disease and gastroesophageal reflux disease: a national cross-sectional cohort study. BMC Pulm Med. 2013; 13(1): 51.
17. cdc. gov [homepage on the Internet]. Chronic obstructive pulmonary disease among adults-United States, 2011. Centers for Disease Control and Prevention; 2012 [updated November 23, 2012; cited July 6, 2013]. Available from: http://www. cdc. gov/mmwr/preview/mmwrhtml/mm6146a2. htm. Accessed February 26, 2014.
18. Centers for Disease Control and Prevention (CDC). Chronic obstructive pulmonary disease among adults-United States, 2011. MMWR Morb Mortal Wkly Rep. 2012; 61(46): 938-943.
19. Menzin J, Boulanger L, Marton J, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in a US Medicare population. Respir Med. 2008; 102(9): 1248-1256.
20. cms. gov [homepage on the Internet]. Medicare Current Beneficiary Survey. Centers for Medicare and Medicaid Services; 2013 [updated July 18, 2013; cited August 6, 2013]. Available from: http://www. cms. gov/Research-Statistics-Data-and-Systems/Research/MCBS/index. html?redirect=/MCBS. Accessed February 26, 2014.
21. Dalal AA, Shah M, va AO, Chaudhari S, Crater G. Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population. Int J Chron Obstruct Pulmon Dis. 2012; 7: 11-19.
22. Halpern R, Baker CL, Su J, et al. Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease. Patient Prefer Adherence. 2011; 5: 375-388.
23. Make B, Dutro MP, Paulose-Ram R, Marton JP, Mapel DW. Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients. Int J Chron Obstruct Pulmon Dis. 2012; 7: 1-9.
24. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying individuals with physician diagnosed COPD in health administrative databases. COPD. 2009; 6(5): 388-394.
25. bls. gov [homepage on the Internet]. Consumer price index. Bureau of Labor Statistics, Department of Labor; 2001 [updated October 16, 2001; cited August 10, 2013]. Available from: http://www. bls. gov/cpi/cpiovrvw. htm. Accessed February 26, 2014.
26. Gerson LB, McLaughlin T, Balu S, Jackson J, Lunacsek O. Variation of health-care resource utilization according to GERD-associated complications. Dis Esophagus. 2012; 25(8): 694-701.
27. Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995; 36(1): 1-10.
28. Halvorsen RP, Palmquist R. The interpretation of dummy variables in semilogarithmic equations. Am Econ Rev. 1980; 70(3): 474-475.
29. Blinder AS. Wage discrimination: Reduced form and structural estimates. J Hum Resour. 1973; 8(4): 436-455.
30. Oaxaca R. Male-female wage differentials in urban labor markets. Int Econ Rev. 1973; 14(3): 693-709.
31. Cotton J. On the decomposition of wage differentials. Rev Econ Stat. 1988; 70(2): 236-243.
32. Newumark D. Employers' discriminatory behavior and the estimation of wage discrimination. J Hum Resour. 1988; 23(3): 279-295.
33. Oaxaca RL, Ransom MR. Identification in detailed wage decompositions. Rev Econ Stat. 1999; 81(1): 154-157.
34. Reimers CW. Labor market discrimination against hispanic and black men. Rev Econ Stat. 1983; 65(4): 570-579.
35. Morehead RS. Gastro-oesophageal reflux disease and non-asthma lung disease. Eur Respir Rev. 2009; 18(114): 233-243.
36. Briggs DD, Doherty DE. Long-term pharmacologic management of patients with chronic obstructive pulmonary disease. Clin Cornerstone. 2004; Suppl 2: S17-S28.
37. Turbyville JC. Applying principles of physics to the airway to help explain the relationship between asthma and gastroesophageal reflux. Med Hypotheses. 2010; 74(6): 1075-1080.
38. O'Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006; 3(2): 180-184.
39. El-Serag H, Hill C, Jones R. Systematic review: the epidemiology of gastro-oesophageal reflux disease in primary care, using the UK General Practice Research Database. Aliment Pharmacol Ther. 2009; 29(5): 470-480.
40. Ajmera M, Wilkins TL, Findley PA, Sambamoorthi U. Multimorbidity, mental illness, and quality of care: Preventable hospitalizations among Medicare beneficiaries. Int J Family Med. 2012; 2012: 823294.
41. Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011; 10(4): 430-439.
42. Centers for Medicare and Medicaid Services. CMS finalizes physician payment rates for 2014 [press release]. Baltimore, MD: Centers for Medicare and Medicaid Services; 2013 [November 27]. Available from: http://www. cms. gov/Newsroom/MediaReleaseDatabase/Press-Releases/2013-Press-Releases-Items/2013-11-27-2. html. Accessed December 05, 2013.
43. Cooke CR, Joo MJ, Anderson SM, et al. The validity of using ICD-9 codes and pharmacy records to identify patients with chronic obstructive pulmonary disease. BMC Health Serv Res. 2011; 11: 37.